slno,preds
0,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze several key factors:

1. **Tumor Characteristics**: The report indicates two distinct adenocarcinomas: one measuring 1 cm and the other 3.5 cm. Both tumors have free surgical margins, which is a positive sign as it suggests that the tumors were completely removed during surgery.

2. **Lymph Node Involvement**: Importantly, there is no evidence of lymph node metastasis. This is a critical factor because the absence of metastasis generally correlates with a better prognosis.

3. **Molecular Studies**: The presence of a positive KRAS mutation is noted. KRAS mutations are often associated with a poorer prognosis in lung adenocarcinomas. However, the absence of EGFR mutations is also mentioned, which is relevant since EGFR mutations can sometimes be targeted with specific therapies that improve outcomes.

4. **Additional Findings**: The report mentions emphysema, which can complicate lung cancer cases but does not directly indicate a poor prognosis on its own.

5. **Morphological Distinction**: The tumors are described as morphologically distinct, suggesting they may be separate primary cancers. This could imply a more complex clinical scenario, but the fact that they are both localized and without lymph node involvement is favorable.

Considering these factors, while the presence of the KRAS mutation is concerning, the overall picture of localized disease with no lymph node involvement and free margins suggests a potentially favorable outcome. 

Therefore, based on the information provided, it is reasonable to conclude that the patient may survive after 2.48 years.

Answer - {""Survival"": ""True""}"
1,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a moderately differentiated adenocarcinoma measuring 2.0 x 2.0 x 1.6 cm. The size of the tumor is significant, but it is classified as T2, which indicates a tumor size greater than 3 cm but less than or equal to 5 cm. However, in this case, the tumor is smaller than 3 cm, which is a positive factor.

2. **Lymph Node Involvement**: The report states that multiple lymph nodes were biopsied and all were negative for neoplasm. This is a crucial point as the absence of lymph node involvement (N0) suggests a lower risk of metastasis.

3. **Pleural Invasion**: There is focal pleural invasion noted, which can be concerning as it indicates that the tumor has begun to invade surrounding structures. However, the absence of lymphovascular space invasion is a positive sign, indicating that the cancer has not spread through the lymphatic or vascular systems.

4. **Final Staging**: The final staging of the tumor is T2N0, which is relatively favorable. T2N0 indicates that while there is a tumor present, it has not spread to lymph nodes, which is a good prognostic factor.

Considering these points, the patient has a moderately differentiated adenocarcinoma with no lymph node involvement and only focal pleural invasion. While the presence of pleural invasion is a concern, the overall staging (T2N0) suggests a better prognosis.

Based on this analysis, it is reasonable to conclude that the patient has a chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
2,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as adenocarcinoma with a lepidic pattern, which is typically associated with a better prognosis. It measures 2.8 cm and is well-differentiated, indicating a less aggressive form of cancer.

2. **Invasiveness**: The report states that the tumor is minimally invasive, which is a positive sign. There is no lymphovascular invasion or visceral pleura invasion, both of which are factors that could worsen the prognosis.

3. **Surgical Margins**: The surgical margins are negative, meaning that there is no cancer present at the edges of the resected tissue. This is crucial as it suggests that the tumor has been completely removed.

4. **Lymph Node Examination**: The lymph node examinations showed no malignancy in the sampled nodes. This is significant because the absence of cancer in the lymph nodes indicates that the cancer has not spread, which is a favorable prognostic factor.

5. **Staging**: The tumor is classified as pT1b, pN1. The pT1b stage indicates a small tumor size (2.8 cm) with no significant spread, and pN1 indicates that there is some involvement of lymph nodes, but since they are negative for malignancy, this is less concerning.

Considering all these factors, the overall prognosis appears to be favorable. The well-differentiated, minimally invasive nature of the tumor, along with negative margins and no lymph node involvement, suggests a high likelihood of survival.

Based on this analysis, the answer is:

{""Survival"": ""True""}"
3,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Type and Differentiation**: The report indicates a diagnosis of moderately-poorly differentiated adenocarcinoma. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Tumor Size**: The maximum tumor size is 2.5 x 2.0 cm. While this size is relatively small, the differentiation and lymph node involvement are more critical factors in prognosis.

3. **Lymph Node Involvement**: Out of twelve examined lymph nodes, ten are involved with metastatic carcinoma, including the subcarinal lymph node. This high rate of lymph node involvement is a significant negative prognostic factor, indicating that the cancer has spread beyond the primary site.

4. **Surgical Margins**: The surgical margins are negative for tumor, which is a positive aspect, suggesting that the tumor was completely resected at the time of surgery.

5. **Lymphovascular Invasion**: The presence of extensive lymphovascular invasion is concerning as it indicates a higher likelihood of metastasis and recurrence.

Considering these factors, the extensive lymph node involvement and lymphovascular invasion suggest a more aggressive disease course, which typically correlates with a poorer prognosis. Given the high likelihood of metastasis and the aggressive nature of the tumor, it is reasonable to conclude that the patient may not survive after 2.48 years.

Answer - {""Survival"": ""False""}"
4,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as an invasive poorly differentiated adenocarcinoma measuring 2.7 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Invasion**: The tumor is noted to invade the visceral pleura, which is a concerning feature as it indicates a more aggressive disease. Additionally, there is intratumoral large vessel invasion, which further suggests a higher risk of metastasis and poorer outcomes.

3. **Lymph Node Involvement**: The level 5 lymph node resection revealed two anthracotic lymph nodes that were negative for metastatic carcinoma. This is a positive finding, as it indicates that there is no lymphatic spread detected in the examined lymph nodes.

4. **Pleural Biopsy**: The left pleural biopsy showed chronic inflammation but was negative for carcinoma, which is also a favorable finding as it suggests that the cancer has not spread to the pleura.

5. **Staging**: The tumor is staged as pT2a, which indicates a tumor size of 2-5 cm with local invasion but no distant metastasis identified. The absence of distant metastasis is a positive prognostic factor.

6. **Margins**: The report mentions a parenchymal margin of 8 mm, which is relatively clear, suggesting that the tumor has not extensively invaded surrounding tissues.

Considering these factors, while the tumor is poorly differentiated and has visceral pleural invasion, the absence of lymph node involvement and distant metastasis, along with the clear margins, suggests that the patient may have a chance of survival beyond 2.48 years.

Based on this analysis, the final answer is:

{""Survival"": ""True""}"
5,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Diagnosis**: The patient has invasive mucinous adenocarcinoma, which is a subtype of lung cancer. The size of the tumor is 2.5 cm, which is relatively small.

2. **Margins**: The report states that the surgical margins are clear, indicating that the tumor has been completely excised with no residual tumor left behind. This is a positive factor for survival.

3. **Lymph Nodes**: All examined lymph nodes (levels 4, 7, and 10) were negative for carcinoma. This suggests that there is no regional lymph node metastasis, which is another favorable indicator for prognosis.

4. **Molecular Studies**: The presence of a KRAS mutation (p.G12C) is noted, which is associated with a poorer prognosis and potential resistance to certain therapies. However, the absence of EGFR mutations is also mentioned, which could influence treatment options.

5. **Overall Assessment**: Despite the presence of a KRAS mutation, the clear surgical margins and negative lymph nodes are strong indicators of a better prognosis. The tumor's small size and lack of metastasis are significant positive factors.

Considering these points, the overall prognosis appears to be favorable despite the KRAS mutation. Therefore, it is reasonable to conclude that the patient has a good chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
6,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates an invasive grade 3 adenocarcinoma with a size of 5 x 4 x 3 cm. Grade 3 tumors are poorly differentiated, which typically correlates with a more aggressive behavior and poorer prognosis.

2. **Lymph Node Involvement**: One of the six intrapulmonary peribronchial lymph nodes tested positive for metastatic adenocarcinoma. The presence of metastasis in lymph nodes is a significant factor that negatively impacts survival rates.

3. **Margins**: The bronchial margins are reported as negative, which is a positive aspect as it suggests that the tumor has not invaded the bronchial tissue.

4. **Other Findings**: The wedge excision of the right upper lobe showed necrotizing granuloma, which is not related to the malignancy. Additionally, multiple lymph nodes from the mediastinum showed necrotizing granulomatous lymphadenitis but were negative for tumor, indicating that while there is inflammation, there is no evidence of metastatic disease in those lymph nodes.

Considering the aggressive nature of the grade 3 adenocarcinoma and the positive lymph node involvement, the prognosis is likely poor. The presence of metastasis in lymph nodes is a critical factor that often leads to decreased survival rates.

Based on these considerations, the conclusion is that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
7,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we can analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as moderately differentiated adenocarcinoma measuring 2.3 cm. This size indicates a relatively small tumor, which is generally associated with a better prognosis.

2. **Invasion and Margins**: The carcinoma extends to within 1 mm of the staple line but does not invade the visceral pleura. This suggests that while there is close proximity to surgical margins, there is no direct invasion into surrounding structures, which is a positive sign.

3. **Lymph Node Involvement**: Importantly, no metastatic carcinoma was identified in the examined lymph nodes. This is a critical factor, as the absence of lymph node involvement (N0) indicates that the cancer has not spread beyond the primary site, which significantly improves the prognosis.

4. **Staging**: The final staging is pT1b N0, which classifies the tumor as localized (T1b) without lymph node involvement (N0). This staging typically correlates with a favorable outcome and a higher likelihood of survival.

5. **Clinical Correlation and Follow-Up**: The recommendation for clinical correlation and follow-up suggests that the medical team is optimistic about monitoring the patient's condition, which is another positive indicator.

Considering these factors, the prognosis appears to be favorable, and the likelihood of survival after 2.48 years is high.

Answer - {""Survival"": ""True""}"
8,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates that the patient has invasive moderately differentiated adenocarcinoma in the right upper lobe. The differentiation of the tumor is moderate, which is generally associated with a better prognosis compared to poorly differentiated tumors.

2. **Lymph Node Involvement**: There is metastatic involvement in one of four hilar lymph nodes. While lymph node involvement is a negative prognostic factor, having only one involved lymph node out of four examined is relatively favorable.

3. **Surgical Margins**: The surgical margins, including the bronchial resection margin, are negative for carcinoma. This suggests that the tumor has been adequately removed, which is a positive indicator for survival.

4. **Pleural Involvement and Angiolymphatic Invasion**: There is no evidence of pleural involvement or angiolymphatic invasion. The absence of these factors is significant as they are associated with a higher risk of metastasis and poorer outcomes.

Considering these points, the presence of only one involved lymph node, negative surgical margins, and no pleural or angiolymphatic invasion suggests a relatively favorable prognosis. Therefore, it is reasonable to conclude that the patient has a good chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
9,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as an invasive well-differentiated adenocarcinoma with a predominant bronchiolo-alveolar carcinoma component. Well-differentiated tumors generally have a better prognosis compared to poorly differentiated ones.

2. **Size of the Tumor**: The tumor measures approximately 50 x 60 x 45 mm, which is relatively large. However, the differentiation and lack of aggressive features are more critical in assessing prognosis.

3. **Vascular and Perineural Invasion**: There is no evidence of vascular or perineural invasion. This is a positive sign, as the absence of these features typically indicates a lower likelihood of metastasis and a better overall prognosis.

4. **Lymph Node Involvement**: The report states that there are no metastases to the hilar lymph nodes. This is significant because lymph node involvement is a critical factor in staging and prognosis.

5. **Pleural Involvement**: The tumor closely abuts the pleural surface, but confirmatory stains suggest that the pleura is likely not involved. This is another favorable aspect, as pleural involvement can indicate a more advanced stage of cancer.

6. **Additional Findings**: The presence of a separate specimen showing features consistent with a lipoma, with no evidence of malignancy, indicates that there are no additional malignancies complicating the patient's condition.

Considering all these factors, the patient has a well-differentiated tumor with no evidence of aggressive features, no lymph node involvement, and no pleural invasion. These factors suggest a better prognosis and a higher likelihood of survival.

Based on this analysis, the final answer is:

{""Survival"": ""True""}"
10,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as poorly differentiated adenocarcinoma, which generally indicates a more aggressive form of cancer with a worse prognosis compared to well-differentiated tumors.

2. **Tumor Size**: The tumor measures 3 x 3 x 3 cm. Tumor size can be an important factor in staging and prognosis, with larger tumors often associated with a higher risk of metastasis.

3. **Invasion**: The tumor has invaded the visceral pleura. This is a significant finding as pleural invasion is associated with a higher likelihood of metastatic spread and can indicate a more advanced stage of cancer.

4. **Lymph Node Involvement**: There is metastasis in 1 out of 1 examined lymph node. The presence of lymph node metastasis is a critical factor in determining prognosis, as it suggests that the cancer has spread beyond the primary site.

5. **Immunohistochemical Staining**: The immunohistochemical profile shows positivity for markers typically associated with lung adenocarcinoma (CD15, CK7, TTF1, CEA) and negativity for markers associated with colorectal cancer (CK20, CDX2). This supports the diagnosis of lung adenocarcinoma but does not directly influence survival.

Considering these factors, the presence of poorly differentiated adenocarcinoma, visceral pleural invasion, and lymph node metastasis suggests a more advanced disease state with a poorer prognosis. Therefore, it is likely that the patient may not survive after 2.48 years.

Answer - {""Survival"": ""False""}"
11,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key features of the tumor:

1. **Tumor Size and Type**: The tumor is located in the left lower lobe and measures 4.0 x 3.5 x 2.0 cm. It is classified as adenocarcinoma of mixed subtype, predominantly papillary. Papillary adenocarcinomas generally have a better prognosis compared to other subtypes.

2. **Invasion**: The report indicates infiltration of the visceral pleura. This is a concerning feature as it suggests a more aggressive behavior of the tumor and may indicate a higher risk of metastasis.

3. **Pathological Classification**: The tumor is classified as pT2, which indicates a tumor size greater than 3 cm but less than or equal to 5 cm. This classification is significant as it suggests a moderate stage of the disease.

4. **Lymph Node Involvement**: Importantly, there is no regional lymph node involvement (0/20 lymph nodes examined). This is a positive sign, as the absence of lymph node metastasis is associated with a better prognosis.

5. **Distant Metastasis Status**: The distant metastasis status is unknown (pMx). This uncertainty can complicate the prognosis, as the presence of distant metastasis would significantly affect survival.

6. **Tumor Grade**: The tumor grade is G2, indicating moderate differentiation. Generally, moderately differentiated tumors have a better prognosis than poorly differentiated ones.

Considering these factors, the absence of lymph node involvement is a strong positive indicator for survival. However, the infiltration of the visceral pleura raises concerns about the potential for aggressive behavior and metastasis. The unknown status of distant metastasis adds uncertainty to the prognosis.

Overall, while there are concerning features, the lack of lymph node involvement and the moderate differentiation suggest that the patient has a reasonable chance of survival over the specified time frame.

Answer - {""Survival"": ""True""}"
12,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is a moderately differentiated adenocarcinoma measuring 2.7 cm. The differentiation suggests that the tumor is not poorly differentiated, which is generally associated with a better prognosis.

2. **Invasion and Margins**: There is no angiolymphatic invasion or pleural involvement, which are positive indicators for survival. Additionally, the bronchial margin is negative, meaning there is no tumor at the resection edge, which reduces the risk of local recurrence.

3. **Lymph Node Involvement**: Metastatic adenocarcinoma was found in 1 out of 4 peribronchial lymph nodes. While lymph node involvement is a negative prognostic factor, having only one positive lymph node out of four examined is relatively favorable compared to more extensive lymph node involvement.

4. **Overall Assessment**: The absence of angiolymphatic invasion, pleural involvement, and negative surgical margins, combined with limited lymph node involvement, suggests a better prognosis. 

Considering these factors, the overall assessment leans towards a favorable outcome for the patient.

Final Answer - {""Survival"": ""True""}"
13,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Size and Differentiation**: The tumor is 1.2 cm in size and is classified as moderately to poorly differentiated. Smaller tumors generally have a better prognosis, but the differentiation grade can impact the aggressiveness of the cancer.

2. **Surgical Margins**: All surgical margins are free of tumor, which is a positive indicator as it suggests that the tumor was completely removed during surgery.

3. **Visceral Pleural Invasion**: There is focal invasion into the visceral pleura. While this indicates a more aggressive behavior, it is focal and not extensive, which may still allow for a favorable outcome.

4. **Lymphatic Invasion**: There is a focus suggestive of lymphatic invasion, but it is not confirmed. This could indicate a risk for metastasis, but since there is no lymph node involvement detected among the seven examined, this is a positive sign.

5. **Lymph Node Involvement**: The absence of lymph node involvement is crucial as it suggests that the cancer has not spread beyond the primary site, which significantly improves the prognosis.

6. **Further Mutation Analysis**: The recommendation for further mutation analysis for EGFR and KRAS indicates that there may be targeted therapy options available, which could improve treatment outcomes.

Considering these factors, the presence of a small tumor size, free surgical margins, and no lymph node involvement are strong indicators of a potentially favorable prognosis. Although there are concerns regarding pleural invasion and lymphatic invasion, the overall findings suggest that the patient has a reasonable chance of survival.

Based on this analysis, the conclusion is that the patient is likely to survive after 2.48 years.

Answer - {""Survival"": ""True""}"
14,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a grade III adenocarcinoma, which is poorly differentiated and typically associated with a worse prognosis compared to well-differentiated tumors. The tumor measures 4 cm and invades the visceral pleura, which is a concerning feature as it suggests a more aggressive disease.

2. **Lymph Node Involvement**: The presence of metastatic adenocarcinoma in two out of four examined lymph nodes indicates that the cancer has spread beyond the primary site. This is significant because lymph node involvement is a critical factor in staging and prognosis.

3. **Staging**: The tumor is staged as pT2, N2, Mx. The ""N2"" classification indicates that there is involvement of lymph nodes that are not just nearby (N1) but also more distant, which typically correlates with a higher stage of disease and a poorer prognosis. The ""Mx"" indicates that the presence of distant metastasis is not assessed, but the involvement of N2 lymph nodes is already a negative prognostic factor.

Considering these factors, the presence of a poorly differentiated tumor, visceral pleural invasion, and lymph node metastasis suggests a more advanced disease state, which is likely to impact survival negatively.

Based on this analysis, the conclusion is that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
15,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates an invasive moderately differentiated adenocarcinoma measuring 9.2 cm. The size of the tumor is significant, as larger tumors generally correlate with a worse prognosis.

2. **Invasion**: The tumor has invaded the chest wall, which is a critical factor. Tumors that invade surrounding structures typically indicate a more advanced stage of cancer and can lead to a poorer prognosis.

3. **Margins**: The report states that the margins are negative for carcinoma, which is a positive aspect as it suggests that the tumor has been completely excised without residual cancer at the edges of the surgical specimen.

4. **Lymph Node Involvement**: Importantly, the report mentions that multiple lymph nodes and a peribronchial biopsy from the right side are negative for carcinoma, with no evidence of malignancy found in 19 examined peribronchial lymph nodes. This is a favorable finding, as it suggests that the cancer has not spread to the lymphatic system, which is often a critical factor in determining prognosis.

5. **Pathological Staging**: The tumor is classified as pT3, which indicates a locally advanced tumor. While this is concerning, the absence of lymph node involvement is a significant positive factor.

Considering these points, the presence of a large tumor with chest wall invasion (pT3) is concerning, but the lack of lymph node involvement is a strong positive indicator. The overall prognosis would depend on various factors, including the patient's overall health, response to treatment, and follow-up care.

Given the combination of a large tumor size and local invasion, despite the negative lymph nodes, the prognosis may still be guarded.

Final assessment: The patient may face challenges due to the tumor's characteristics, but the absence of lymph node involvement provides a more optimistic outlook.

Answer - {""Survival"": ""False""}"
16,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Diagnosis of Adenocarcinoma**: The report indicates that the patient has a moderately differentiated adenocarcinoma in the left lower lobe measuring 6.9 cm. This is a significant tumor size, which is a negative prognostic factor.

2. **Visceral Pleural Invasion**: The presence of visceral pleural invasion suggests that the tumor has penetrated the pleura, which can indicate a more aggressive disease and a higher likelihood of metastasis.

3. **Lymphangitic Invasion**: This finding indicates that cancer cells may be spreading through the lymphatic system, which is another concerning sign for prognosis.

4. **Regional Lymph Node Involvement**: The report states that metastatic adenocarcinoma was found in multiple lymph nodes (one from left level 9 and two out of five from left level 11). This indicates that the cancer has spread to nearby lymph nodes, which is a critical factor in staging and prognosis.

5. **No Distant Metastasis**: While there is no evidence of distant metastasis noted, the presence of regional lymph node involvement and the characteristics of the tumor (size, pleural invasion, and lymphangitic invasion) suggest a more advanced stage of cancer.

Considering these factors, the prognosis for a patient with a moderately differentiated adenocarcinoma of this size, with visceral pleural invasion and lymph node involvement, is generally poor. The presence of multiple adverse features typically correlates with a lower survival rate.

Based on this analysis, it is reasonable to conclude that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
17,"Reasoning Steps:
1. The pathology report does not provide any specific diagnostic information about the tumor type, grade, stage, or any other relevant clinical details that would allow for an assessment of the patient's prognosis.
2. Without any information regarding the tumor's characteristics, such as differentiation, size, lymph node involvement, or metastasis, it is impossible to determine the likelihood of survival.
3. Given the lack of critical information in the report, we cannot conclude whether the patient will survive or not.

Answer - {""Survival"": ""False""}"
18,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Type and Differentiation**: The tumor is a well-differentiated papillary non-mucinous adenocarcinoma. Well-differentiated tumors generally have a better prognosis compared to poorly differentiated ones.

2. **Tumor Size and Location**: The tumor measures 50 mm (5 cm) and is located in the right lower lobe. It is classified as pT2, which indicates a tumor size greater than 3 cm but less than or equal to 5 cm.

3. **Lymph Node Involvement**: The report states pN0, indicating no lymph node involvement. This is a positive prognostic factor, as the absence of lymph node metastasis is associated with a better chance of survival.

4. **Distant Metastasis**: The report indicates pMX, which means that the presence of distant metastasis is not assessed, but there is no indication of metastasis in the report.

5. **Margins**: The resection margins are clear of tumor (R0), which is crucial for reducing the risk of local recurrence.

6. **Additional Findings**: The report mentions subpleural scarring and pleural adhesions, which are not directly related to the malignancy but do not indicate a worse prognosis.

Considering these factors, the patient has a well-differentiated tumor with no lymph node involvement, clear margins, and no evidence of distant metastasis. These characteristics suggest a favorable prognosis.

Based on this analysis, it is reasonable to conclude that the patient is likely to survive after 2.48 years.

Answer - {""Survival"": ""True""}"
19,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a poorly differentiated adenocarcinoma measuring 4.5 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Invasion**: There is visceral pleural invasion and lymphovascular invasion noted. The presence of these invasions typically suggests a more aggressive disease and a higher likelihood of metastasis.

3. **Lymph Node Involvement**: One of the six lymph nodes examined contains metastatic carcinoma with extracapsular extension. Extracapsular extension is a significant factor that indicates a higher risk of recurrence and poorer overall survival.

4. **Staging**: The tumor is staged as pT2aN1MX. The presence of N1 indicates that there is regional lymph node involvement, which is a negative prognostic factor.

Considering these factors, the presence of poorly differentiated adenocarcinoma, visceral pleural invasion, lymphovascular invasion, and positive lymph nodes with extracapsular extension suggests a more advanced disease with a higher likelihood of poor outcomes.

Based on this analysis, it is reasonable to conclude that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
20,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key elements of the report:

1. **Tumor Type**: The report indicates a poorly differentiated bronchiolo-alveolar adenocarcinoma. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Tumor Size**: The tumor measures 2.5 x 1.5 x 3 cm. While the size is not excessively large, the differentiation grade is more critical in this context.

3. **Lymph Node and Invasion Details**: The report lacks information regarding lymph node involvement, vascular invasion, or any other metastatic spread. The absence of this information makes it difficult to assess the overall stage and prognosis accurately.

4. **General Prognosis**: Poorly differentiated adenocarcinomas tend to have a higher likelihood of metastasis and poorer outcomes. Without additional information on lymph node involvement or metastasis, it is challenging to provide a definitive prognosis.

Given the poorly differentiated nature of the tumor and the lack of detailed staging information, it is reasonable to conclude that the prognosis is likely unfavorable.

Based on this reasoning, the final answer is:

{""Survival"": ""False""}"
21,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we can analyze the key findings:

1. **Tumor Characteristics**: The tumor is a moderately differentiated adenocarcinoma measuring 2.5 cm. Moderately differentiated tumors typically have a better prognosis compared to poorly differentiated tumors.

2. **Margins**: The report states that the surgical margins are negative, indicating that the tumor has been completely resected without any cancer cells at the edges of the removed tissue. This is a positive sign for survival.

3. **Vascular and Lymphatic Invasion**: There is no evidence of vascular or lymphatic invasion. This is significant because the absence of invasion suggests a lower likelihood of metastasis, which is favorable for survival.

4. **Lymph Node Involvement**: All examined regional lymph nodes (five in total) are negative for malignancy. This indicates that the cancer has not spread to the lymph nodes, which is a critical factor in determining prognosis.

5. **Pleural Invasion**: The tumor shows invasion towards the pleural surface but does not directly involve the visceral pleura. While pleural invasion can be concerning, the lack of direct involvement of the visceral pleura and the absence of lymph node metastasis are strong indicators of a better prognosis.

Considering all these factors, the overall assessment suggests that the patient has a favorable prognosis and is likely to survive beyond 2.48 years.

Answer - {""Survival"": ""True""}"
22,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a poorly differentiated adenocarcinoma in the right upper lobe, which is generally associated with a poorer prognosis compared to well-differentiated tumors.

2. **Tumor Size**: The tumor size is approximately 1.7 cm. While this is relatively small, the differentiation and presence of metastasis are more critical factors in prognosis.

3. **Metastatic Involvement**: The presence of metastatic carcinoma in multiple lymph nodes (specifically at levels 7 and 12) is a significant concern. Metastasis indicates that the cancer has spread beyond the primary site, which typically correlates with a worse prognosis.

4. **Capsular Penetration and Lymphatic Invasion**: The report mentions capsular penetration and lymphatic invasion, both of which are indicators of aggressive disease and further support the likelihood of poor outcomes.

5. **Surgical Margins**: Although the surgical margins are negative for carcinoma, which is a positive aspect, the presence of metastasis and the characteristics of the tumor overshadow this finding.

Considering these factors, the presence of poorly differentiated adenocarcinoma with metastasis in multiple lymph nodes suggests a poor prognosis. Therefore, it is likely that the patient will not survive after 2.48 years.

Answer - {""Survival"": ""False""}"
23,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a moderately differentiated adenocarcinoma measuring 2.0 cm in the right upper lobe. The size of the tumor is relatively small, which is generally a positive prognostic factor.

2. **Surgical Margins**: The surgical margins are clear, meaning that the tumor has been completely excised without any cancerous cells at the edges of the removed tissue. This is another favorable sign for the patient's prognosis.

3. **Lymph Node Involvement**: The report states that all examined lymph nodes, including those at levels IX and XI, are negative for malignancy. This indicates that there is no evidence of metastasis, which significantly improves the likelihood of survival.

4. **Pleural Involvement**: There is no pleural involvement noted, which further suggests that the cancer has not spread beyond the lung.

Considering these factors, the overall assessment points towards a localized lung adenocarcinoma with no evidence of metastasis. Such a scenario typically correlates with a better prognosis and a higher chance of survival.

Based on this analysis, the conclusion is that the patient is likely to survive after 2.48 years.

Answer - {""Survival"": ""True""}"
24,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is classified as adenocarcinoma, measuring 6.5 x 6.5 x 5.0 cm. This size indicates a significant tumor burden.

2. **Tumor Stage**: The tumor is classified as pT2b, which indicates a tumor size greater than 5 cm but less than or equal to 7 cm. The classification pN1 indicates that there are 6 out of 28 lymph nodes involved with metastatic disease. This suggests a moderate level of lymph node involvement.

3. **Histological Grade**: The tumor is graded as G3, which indicates poorly differentiated adenocarcinoma. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

4. **Proliferation Index**: The Ki-67 proliferation index of 40% indicates a high level of cell proliferation, which is often associated with more aggressive tumor behavior.

5. **Pleural Invasion**: The report states that there is no infiltration of the visceral pleura, which is a positive factor, as pleural invasion is often associated with a worse prognosis.

Considering these factors, the presence of a large tumor size, significant lymph node involvement, and a high proliferation index suggest a more aggressive disease course. While the absence of pleural invasion is favorable, the overall findings indicate a higher risk of disease progression.

Based on this analysis, it is likely that the patient may not survive after 2.48 years due to the aggressive nature of the tumor and the extent of lymph node involvement.

Answer - {""Survival"": ""False""}"
25,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Diagnosis of Metastatic Adenocarcinoma**: The report indicates that the patient has metastatic adenocarcinoma, which is a significant concern as it suggests that the cancer has spread beyond the primary site.

2. **Lymph Node Involvement**: Eight out of twelve lymph nodes from the left lung are positive for cancer. This high rate of lymph node involvement indicates a more advanced stage of cancer, which typically correlates with a poorer prognosis.

3. **Tumor Characteristics**: The tumor is described as moderately to poorly differentiated, measuring 5.0 x 4.1 x 2.4 cm. Poorly differentiated tumors tend to be more aggressive and have a worse prognosis compared to well-differentiated tumors.

4. **Lymphovascular Invasion**: The presence of lymphovascular invasion is another negative prognostic factor, as it suggests that the cancer has the potential to spread further through the lymphatic and vascular systems.

5. **Direct Extension into Lymph Nodes**: The report mentions direct extension into two intraparenchymal lymph nodes, which further indicates an advanced disease state.

6. **Molecular Analysis**: The molecular analysis for EGFR mutations was negative, which may limit treatment options, as certain targeted therapies are not applicable.

Given these factors, the presence of metastatic disease, significant lymph node involvement, and aggressive tumor characteristics suggest a poor prognosis for survival beyond 2.48 years.

Based on this analysis, the conclusion is that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
26,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates an invasive adenocarcinoma in the left upper lobe, measuring 3.5 cm. The tumor is classified as histologic grade 2/4, which suggests a moderate differentiation. 

2. **Lymph Node Involvement**: The report states that most lymph nodes were free of tumor, but hilar node #2 contained metastatic adenocarcinoma. This indicates that there is some degree of spread, but it is limited to one lymph node.

3. **Invasion and Margins**: There is no invasion of the visceral pleura or large vessels, which is a positive sign. Additionally, the resection margins are clear of tumor, indicating that the surgical removal was effective in removing the tumor.

4. **TNM Staging**: The tumor is classified as pT2a (indicating a tumor size between 3-5 cm), pN1 (indicating involvement of regional lymph nodes), and pMX (indicating that distant metastasis cannot be assessed). This staging suggests that the cancer is localized with some regional spread but does not indicate advanced disease.

Considering these factors, the presence of only one involved lymph node and clear surgical margins, along with the absence of visceral pleural invasion, suggests a better prognosis. Patients with similar profiles often have a reasonable chance of survival beyond 2.48 years.

Based on this analysis, the conclusion is that the patient is likely to survive after 2.48 years.

Answer - {""Survival"": ""True""}"
27,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Diagnosis**: The patient has adenocarcinoma in the left upper lobe of the lung, which is a type of lung cancer. The presence of different components (solid, acinar, and bronchioloalveolar) suggests a complex tumor.

2. **Tumor Size**: The tumor measures 3.5 x 2.8 x 2.5 cm, which is relatively significant in size. Larger tumors often correlate with a worse prognosis.

3. **Invasion**: The tumor invades the visceral pleura, which is a concerning feature as it indicates a more aggressive disease and potential for spread.

4. **Metastasis**: There is evidence of metastatic adenocarcinoma in peribronchial lymph nodes. The presence of metastasis is a critical factor that negatively impacts survival.

5. **Vascular and Lymphatic Invasion**: While there is no vascular invasion noted, lymphatic invasion is pending, which means we do not have complete information on this aspect. However, the presence of metastasis already suggests that the cancer has spread.

6. **Additional Findings**: The report mentions centrilobular emphysema, pulmonary hemosiderosis, and necrotizing granulomas in the lymph nodes, which may complicate the clinical picture but are not directly related to the prognosis of the adenocarcinoma.

Given the presence of a significant tumor size, visceral pleural invasion, and confirmed metastasis to lymph nodes, these factors collectively indicate a poorer prognosis. The presence of metastatic disease is particularly concerning and suggests that the cancer is not localized and has the potential to progress.

Based on these considerations, it is reasonable to conclude that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
28,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as a poorly differentiated adenocarcinoma measuring 58 mm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Cavitated Tumor**: The presence of cavitation can indicate a more aggressive tumor behavior.

3. **Visceral Pleural Invasion**: The tumor has invaded the visceral pleura, which is a negative prognostic factor as it suggests a higher likelihood of local spread.

4. **Chest Wall Involvement**: The involvement of the chest wall is significant as it indicates that the cancer has spread beyond the lung tissue, which typically correlates with a more advanced stage of disease.

5. **Blood Vessel Invasion**: The presence of blood vessel invasion is concerning as it increases the risk of metastasis to distant sites.

6. **Lymphatic and Perineural Invasion**: While there is no lymphatic or perineural invasion noted, the other factors (pleural invasion, chest wall involvement, and blood vessel invasion) are already significant enough to raise concern.

7. **Lymph Node Status**: The report indicates that no lymph node metastases were found, which is a positive aspect. However, the other aggressive features of the tumor may outweigh this finding.

Given these factors, the presence of a poorly differentiated adenocarcinoma with visceral pleural invasion and chest wall involvement suggests a poor prognosis. The combination of these aggressive features typically indicates a higher likelihood of disease progression and lower survival rates.

Based on this analysis, the conclusion is that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
29,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as poorly differentiated adenocarcinoma, which generally has a worse prognosis compared to well-differentiated tumors. However, the size of the tumor is relatively small at 3.5 x 3 cm.

2. **Invasion**: There is no evidence of venous invasion, which is a positive sign as it suggests that the cancer has not spread through the bloodstream.

3. **Lymph Node Examination**: Seven hilar lymph nodes were examined, and all showed reactive changes without evidence of metastasis. This indicates that the cancer has not spread to the lymph nodes, which is a critical factor in determining prognosis.

4. **Surgical Margins**: The report states that the surgical margins are uninvolved, suggesting that the tumor was completely resected. This is another positive indicator for survival.

Considering these factors, the absence of metastasis in the lymph nodes and the complete resection of the tumor are strong indicators of a favorable prognosis. Although the tumor is poorly differentiated, the overall findings suggest that the patient has a good chance of survival.

Based on this reasoning, the final answer is:

{""Survival"": ""True""}"
30,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a solid predominant adenocarcinoma measuring 3.7 cm. This size suggests a significant tumor burden, but it is classified as Stage IIB, which is still considered early-stage lung cancer.

2. **Lymph Node Involvement**: Importantly, all examined lymph nodes (11 total) are negative for malignancy. This is a positive indicator, as the absence of lymph node involvement typically correlates with a better prognosis.

3. **Invasion**: The report states that there is no visceral pleural invasion or lymph-vascular invasion identified. This further supports a more favorable prognosis, as these factors can indicate a higher risk of metastasis.

4. **Stage Classification**: Stage IIB indicates that the cancer is invasive but has not spread to lymph nodes, which is a critical factor in determining survival rates. 

5. **Ancillary Studies**: The absence of EGFR mutations does not necessarily indicate a poor prognosis, as treatment options may still be available.

Considering these factors, the overall assessment of the patient's condition suggests a relatively favorable prognosis given the absence of lymph node involvement and the lack of invasive characteristics. Therefore, it is reasonable to conclude that the patient has a good chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
31,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is a poorly differentiated adenocarcinoma measuring 3.5 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Invasion**: There is evidence of invasion into the visceral pleura and large vessels. This indicates a more aggressive disease and suggests a higher likelihood of metastasis.

3. **Lymph Node Involvement**: The report states that there are metastases in the ipsilateral peribronchial and hilar lymph nodes. This is significant because lymph node involvement is a critical factor in staging and prognosis. The presence of metastases in regional lymph nodes typically indicates a more advanced stage of cancer.

4. **Negative Lymph Node Biopsies**: While multiple lymph node biopsies from various stations were negative for malignancy, the presence of metastases in other lymph nodes is concerning and suggests that the cancer has spread.

5. **Margins**: The bronchial margins are reported as free of tumor with a distance of 5 mm from the invasive carcinoma to the closest margin. This is a positive aspect, as clear margins can be associated with a better prognosis.

Considering these factors, the presence of poorly differentiated adenocarcinoma, visceral pleural invasion, and lymph node metastases suggests a more advanced stage of cancer, which typically correlates with a poorer prognosis and lower survival rates.

Based on this analysis, it is reasonable to conclude that the patient is unlikely to survive after 2.48 years.

Answer - {""Survival"": ""False""}"
32,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as poorly differentiated adenocarcinoma measuring 2.5 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Surgical Margins**: The surgical margins are uninvolved, which is a positive sign indicating that the tumor has been completely resected without any cancer cells at the edges of the removed tissue.

3. **Visceral Pleural Invasion**: There is a suggestion of visceral pleural invasion. This is concerning as it may indicate a more aggressive tumor behavior and a higher risk of recurrence.

4. **Lymph Node Involvement**: The report states that two lymph nodes from the lobectomy specimen were negative for metastatic disease, which is favorable. However, it also mentions that only the level 12 nodes demonstrated evidence of metastasis. The presence of metastasis in lymph nodes is a significant factor that can affect survival negatively.

5. **Overall Assessment**: The combination of a poorly differentiated tumor, potential visceral pleural invasion, and lymph node metastasis suggests a more advanced disease state. While the uninvolved surgical margins are a positive aspect, the presence of metastasis in lymph nodes typically indicates a poorer prognosis.

Considering these factors, the likelihood of survival after 2.48 years appears to be low due to the aggressive nature of the tumor and the presence of metastasis.

Answer - {""Survival"": ""False""}"
33,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is a poorly differentiated adenocarcinoma measuring 3.5 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Invasion**: The tumor invades the pleura, which is a concerning feature as it indicates a more aggressive disease. However, the surgical margins are negative for tumor, which is a positive aspect as it suggests that the tumor was completely resected.

3. **Vascular Invasion**: The presence of vascular invasion is another negative prognostic factor, as it can indicate a higher likelihood of metastasis.

4. **Lymph Node Involvement**: Importantly, the report states that there is no evidence of regional lymph node involvement or distant metastasis. This is a significant positive factor, as the absence of metastasis greatly improves the prognosis.

Considering these factors, while the tumor is poorly differentiated and has vascular invasion, the lack of lymph node involvement and distant metastasis suggests that the disease may still be manageable. The negative surgical margins also indicate a successful resection.

Based on this analysis, the overall prognosis leans towards survival, despite the aggressive nature of the tumor.

Answer - {""Survival"": ""True""}"
34,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is described as a 2.8 cm invasive moderately differentiated adenocarcinoma located in the right upper lobe. The size and differentiation of the tumor are important factors in assessing prognosis.

2. **Invasion**: The report indicates angiolymphatic and visceral pleural invasion. Angiolymphatic invasion suggests a higher risk of metastasis, which can negatively impact survival. Visceral pleural invasion also indicates a more aggressive tumor behavior.

3. **Lymph Node Status**: All sampled lymph nodes are reported as benign, which is a positive sign. The absence of metastatic involvement in the lymph nodes is crucial for a better prognosis.

4. **Surgical Margins**: The surgical resection margins are free of tumor, which is another favorable factor. Clear margins suggest that the tumor has been adequately removed, reducing the risk of local recurrence.

5. **Pathologic Stage**: The tumor is classified as T2N0MX. The T2 classification indicates a larger tumor size (2.8 cm), but the N0 status (no lymph node involvement) is a positive aspect. The MX indicates that distant metastasis cannot be assessed, which leaves some uncertainty.

6. **Additional Findings**: The presence of chronic inflammation and emphysematous changes may indicate underlying lung issues but do not directly affect the prognosis of the adenocarcinoma.

Considering these factors, the presence of visceral pleural invasion raises concerns about the aggressiveness of the tumor, but the absence of lymph node involvement and clear surgical margins are significant positive indicators. 

Overall, while the tumor has some aggressive features, the lack of lymph node metastasis and clear margins suggest a better chance of survival.

Based on this analysis, the final answer is:

{""Survival"": ""True""}"
35,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Type and Differentiation**: The report indicates a diagnosis of poorly differentiated non-small cell carcinoma (NSCLC) originating from the lung. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors.

2. **Tumor Size**: The maximum tumor size is reported as 5.5 x 5.0 cm. Larger tumors are often associated with a higher stage and worse prognosis.

3. **Lymph Node Involvement**: Importantly, all examined lymph nodes were negative for carcinoma. This is a favorable finding, as the absence of lymph node involvement typically suggests a better prognosis.

4. **Immunohistochemical Staining**: The report shows positive TTF-1 and negative results for other markers, which supports the diagnosis of adenocarcinoma. While the tumor is poorly differentiated, the specific markers can help in understanding the tumor's behavior and potential treatment options.

5. **Pending Further Characterization**: The report mentions that further characterization of the tumor type is pending additional immunoevaluation. This indicates that there may be more information to come, but currently, we base our assessment on the existing data.

Considering these factors, the absence of lymph node involvement is a significant positive indicator for survival, despite the tumor being poorly differentiated and of considerable size. 

Based on this analysis, the conclusion is that the patient has a reasonable chance of survival after 2.48 years.

Answer - {""Survival"": ""True""}"
36,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The report indicates a poorly differentiated adenocarcinoma measuring 7 cm. Poorly differentiated tumors generally have a worse prognosis compared to well-differentiated tumors, but size alone does not determine survival.

2. **Margins**: The report states that there is no invasion of the visceral pleura and that the bronchial and vascular margins are negative. This is a positive sign, as it indicates that the tumor has been successfully resected with clear margins, reducing the likelihood of residual disease.

3. **Lymph Node Involvement**: All examined lymph nodes from levels 4, 7, and 9 showed no evidence of tumor. This is crucial because the absence of metastatic spread to lymph nodes is a strong indicator of a better prognosis.

4. **Overall Findings**: The combination of clear surgical margins and no lymph node involvement suggests that the cancer has been effectively removed and that there is no evidence of metastasis.

Considering these factors, the prognosis appears favorable despite the tumor being poorly differentiated. The absence of metastasis and clear margins significantly improve the chances of survival.

Based on this analysis, the answer is:

{""Survival"": ""True""}"
37,"To determine if the patient will survive after 2.48 years based on the provided pathology report, we need to analyze the key findings:

1. **Tumor Characteristics**: The tumor is a mixed acinar and bronchioloalveolar adenocarcinoma measuring 3.5 cm. The presence of moderate to poorly differentiated histology suggests a more aggressive tumor behavior.

2. **Lymph Node Involvement**: Metastatic adenocarcinoma was found in one of the two resected lymph nodes. This indicates that the cancer has spread beyond the primary site, which is a significant factor in prognosis.

3. **Negative Lymph Nodes**: While the remaining lymph nodes were negative for tumor, the presence of metastasis in even one lymph node is concerning.

4. **KRAS Mutation**: The positive KRAS mutation analysis indicates a mutation in the KRAS gene, which is often associated with a poorer prognosis in lung adenocarcinomas.

Considering these factors, the presence of a moderately differentiated tumor, lymph node metastasis, and a KRAS mutation suggests a higher likelihood of aggressive disease and potential for poor outcomes.

Based on this analysis, the prognosis appears unfavorable, leading to the conclusion that the patient may not survive after 2.48 years.

Answer - {""Survival"": ""False""}"
